# Diabetes Research Hub — Iteration Run Report

**Date:** 2026-07-06 (Monday — weekly literature sweep run)
**Agent:** Automated research agent (scheduled)

## Summary

Vetting complete: all 285 papers remain vetted (272 VETTED / 13 FLAGGED, 0 unvetted).
Credibility sweep CLEAN. Two partially-validated paths reaffirmed. Weekly 7-topic
literature sweep run. Pipeline rebuilt (41/41 stages OK). Local commit succeeded; push
still blocked (requires user).

## 1. Credibility Sweep — CLEAN
- 0 fabricated PMIDs (>42,000,000) in scripts
- 0 "zero SAE" / "zero rejection" claims
- 3 "achieves" hits, all benign & unchanged from prior runs: TTP399 tissue selectivity
  (build_gka_landscape), LADA cost-effectiveness model (build_lada_diagnostic_model),
  microbiome-ML macro-AUC (project_microbiome_ml_phase3). "curative" only in the
  verify_before_deploy detector regex.

## 2. Weekly Literature Sweep (7 topics)
| Topic | Finding | Action |
|---|---|---|
| verapamil / Ver-A-T1D | Adult primary NEGATIVE re-confirmed (see §3) | Path reaffirmed |
| LADA | No new June-2026 trial; recent case series + immunotherapy reviews only | None |
| islet transplant / tegoprubart | Eledon June-2026: IIT now **12/12 insulin-independent** (was 10/10), mean HbA1c ~5.4%, no rejection/DSA/nephrotox — still press/HCPLive/ADA only, **no peer-reviewed pub** | Queue note updated |
| NLRP3 inflammasome / DKD | Reviews reaffirm NLRP3 as target; tissue-specific clinical therapeutics still scarce; no new human readout | None |
| drug repurposing / generic | FDA approved **first generic dapagliflozin (Apr 2026)**; FDA diabetes-repurposing RFI (Fed. Register 2026-05-12) — regulatory context, no new interventional evidence | Noted |
| dapagliflozin + colchicine | No dedicated diabetes trial found (unchanged) | None |
| oxidative stress combination | No new antioxidant RCT with hard glycemic/prevention endpoint | None |

No genuinely new on-topic PMIDs added to the corpus this run.

## 3. Path Validations (×2)

**verapamil → T1D — REAFFIRMED PARTIALLY_VALIDATED.**
Adult Ver-A-T1D primary re-confirmed NEGATIVE: no significant 2h-MMTT C-peptide difference
vs placebo at 12 mo; non-significant trend favoring verapamil. Underpowering re-corroborated
— observed placebo C-peptide decline ~0.09 nmol/L/min (slower than anticipated). Pediatric
CLVer (PMID 36826844, ~30% greater C-peptide at 52 wk) positive and unchanged. Net: positive
pediatric + null adult primary → PARTIALLY_VALIDATED. **Diabetologia DOI 10.1007/s00125-025-06490-8
still NOT independently confirmable** — continue sourcing EASD 2025 + news, not the DOI.
Sources: Breakthrough T1D EASD-2025 recap; News-Medical 2025-09-18; EurekAlert.

**semaglutide → retinopathy (stalest path, last 2026-03-20) — REAFFIRMED PARTIALLY_VALIDATED.**
Early transient retinopathy-worsening signal tied to rapid glycemic improvement (SUSTAIN-6);
long-term effect inconsistent, tends to stabilize after 12–18 mo. 2025 systematic review of
GLP-1RA microvascular outcomes (PMC12547187) corroborates mixed evidence. Definitive FOCUS RCT
(NCT03811561, n=1500) results now expected 2026 (completion 2027) — **added to monitoring watch**.

## 4. Pipeline Rebuild
`run_quality_improvements.py` — all **41/41 stages [OK]**, including live PMID verification
against the PubMed API.

## 5. Git
Local commit succeeded (HEAD `9e7c314`) after clearing stale OneDrive `.git/*.lock` files via
rename. **Push still BLOCKED** — no GitHub auth in sandbox. USER ACTION: `cd Diabetes_Research; git push`.

## Queue changes
- Tegoprubart item updated to 12/12 insulin-independent.
- FOCUS trial (semaglutide retinopathy) added as P6 monitoring watch (~2026-08-06).
- Next-stalest PARTIALLY path for next run set to Treg_expansion → T1D (2026-04-30).
